Current Assets
Accounts Receivable
Bristol-Myers Squibb Accounts Receivable decreased by 17.9% to $9.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 13.3%, from $10.8B to $9.37B. Over 5 years (FY 2020 to FY 2025), Accounts Receivable shows an upward trend with a 6.1% CAGR. This is a positive signal — lower values indicate better performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionCurrent Assets
CategoryEfficiency
SignalLower is better
VolatilityModerate
First reportedQ4 2014
Last reportedQ1 2026Apr 30, 2026
How to read this metric
An increase relative to sales may signal collection issues, while a decrease suggests efficient cash conversion cycles.
Detailed definition
This represents the balance of money owed to the company by customers for goods or services delivered, net of any estima...
Peer comparison
Standard across the industry, though collection periods vary based on the mix of government and private payers.
Metric ID:
accounts_receivable_netHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $9.02B | $9.25B | $9.37B | $8.51B | $9.05B | $9.61B | $9.89B | $10.05B | $10.11B | $10.3B | $10.92B | $10.45B | $11.42B | $11.03B | $10.75B | $10.8B | $11.42B | $11.42B | $11.41B | $9.37B |
| QoQ Change | — | +2.5% | +1.3% | -9.2% | +6.4% | +6.2% | +2.8% | +1.7% | +0.6% | +1.9% | +6.0% | -4.3% | +9.3% | -3.5% | -2.5% | +0.5% | +5.7% | +0.1% | -0.1% | -17.9% |
| YoY Change | — | — | — | — | +0.4% | +4.0% | +5.5% | +18.1% | +11.7% | +7.2% | +10.5% | +3.9% | +13.0% | +7.0% | -1.6% | +3.4% | -0.1% | +3.6% | +6.2% | -13.3% |
Range$8.51B – $11.42B
CAGR+0.8%
Avg YoY Growth+5.0%
Median YoY Growth+4.7%
Current Streak2 quarters decline
Accounts Receivable at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's accounts receivable?
- Bristol-Myers Squibb (BMY) reported accounts receivable of $9.37B in Q1 2026.
- How has Bristol-Myers Squibb's accounts receivable changed year-over-year?
- Bristol-Myers Squibb's accounts receivable decreased by 13.3% year-over-year, from $10.8B to $9.37B.
- What is the long-term trend for Bristol-Myers Squibb's accounts receivable?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's accounts receivable has grown at a 6.1% compound annual growth rate (CAGR), from $8.5B to $11.41B.
- What does accounts receivable mean?
- The amount of money customers owe the company for products already delivered.